<DOC>
	<DOCNO>NCT01412944</DOCNO>
	<brief_summary>The study assess safety efficacy intravenous ( 10mg/kg ) subcutaneous ( 300mg ) secukinumab moderate severe chronic plaque-type psoriasis partial responder secukinumab .</brief_summary>
	<brief_title>Efficacy Safety Intravenous Subcutaneous Secukinumab Moderate Severe Chronic Plaque-type Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Inclusion criterion : Written Informed Consent must obtain assessment perform , Subject must able understand communicate investigator comply requirement study . Subjects must participate study CAIN457A2304 achieve partial response twelve week treatment major protocol deviation . A partial response define achieve â‰¥ PASI 50 &lt; 75 response . Exclusion criterion Pregnant woman lactate woman Forms psoriasis chronic plaque type Ongoing use prohibit psoriasis treatment Ongoing use nonpsoriasis prohibit treatment Previous exposure biologic drug directly target IL17 IL17 receptor , except secukinumab study CAIN457A2304 Active ongoing inflammation disease psoriasis might confound evaluation benefit secukinumab therapy UV therapy excessive exposure sunlight</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Psoriasis</keyword>
	<keyword>plaque</keyword>
	<keyword>inflammatory skin disease</keyword>
	<keyword>scaly patch</keyword>
	<keyword>AIN457</keyword>
	<keyword>secukinumab</keyword>
	<keyword>Moderate severe</keyword>
</DOC>